Bayer (FRA:BAYN) has been given a €70.00 ($81.40) target price by JPMorgan Chase & Co. in a report issued on Thursday, March 28th, Borsen Zeitung reports. The firm presently has a “neutral” rating on the healthcare company’s stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 14.45% from the company’s previous close.
Several other equities research analysts also recently weighed in on the stock. Goldman Sachs Group set a €78.00 ($90.70) target price on shares of Bayer and gave the company a “buy” rating in a research note on Tuesday, December 11th. Barclays set a €80.00 ($93.02) price target on shares of Bayer and gave the stock a “buy” rating in a report on Monday, January 21st. Credit Suisse Group set a €77.00 ($89.53) target price on shares of Bayer and gave the stock a “buy” rating in a report on Monday, December 3rd. Morgan Stanley set a €82.00 ($95.35) target price on shares of Bayer and gave the stock a “buy” rating in a report on Friday, December 14th. Finally, HSBC set a €76.00 ($88.37) price objective on shares of Bayer and gave the company a “neutral” rating in a research report on Thursday, March 21st. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have assigned a buy rating to the stock. Bayer has an average rating of “Hold” and an average target price of €81.80 ($95.12).
Bayer stock traded down €0.38 ($0.44) during mid-day trading on Thursday, reaching €61.16 ($71.12). 4,465,525 shares of the company’s stock traded hands. Bayer has a 12-month low of €91.58 ($106.49) and a 12-month high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Story: Portfolio Manager
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.